96 related articles for article (PubMed ID: 32446962)
1. Exploration of temperature and shelf-life dependency of the therapeutically available Insulin Detemir.
Beji O; Gillis RB; Dinu V; Jiwani SI; Gyasi-Antwi P; Fisk ID; Meal A; Morgan PS; Harding SE; Huang S; Agugini G; Fedele F; Adams GG
Eur J Pharm Biopharm; 2020 Jul; 152():340-347. PubMed ID: 32446962
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of insulin analogues therapeutically available to patients.
Adams GG; Meal A; Morgan PS; Alzahrani QE; Zobel H; Lithgo R; Kok MS; Besong DTM; Jiwani SI; Ballance S; Harding SE; Chayen N; Gillis RB
PLoS One; 2018; 13(3):e0195010. PubMed ID: 29596514
[TBL] [Abstract][Full Text] [Related]
3. Solution structures of long-acting insulin analogues and their complexes with albumin.
Ryberg LA; Sønderby P; Barrientos F; Bukrinski JT; Peters GHJ; Harris P
Acta Crystallogr D Struct Biol; 2019 Mar; 75(Pt 3):272-282. PubMed ID: 30950398
[TBL] [Abstract][Full Text] [Related]
4. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
[TBL] [Abstract][Full Text] [Related]
5. Probing the mechanism of reduced
Brand CL; Sturis J
Expert Opin Drug Metab Toxicol; 2023 Apr; 19(4):225-228. PubMed ID: 37272319
[TBL] [Abstract][Full Text] [Related]
6. Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans.
Porcellati F; Rossetti P; Candeloro P; Lucidi P; Cioli P; Andreoli AM; Ghigo E; Bolli GB; Fanelli CG
J Clin Endocrinol Metab; 2009 Aug; 94(8):3017-24. PubMed ID: 19470629
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of insulin detemir: a systematic review.
Suh DC; Aagren M
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):641-55. PubMed ID: 21961796
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes.
Koehler G; Treiber G; Wutte A; Korsatko S; Mader JK; Semlitsch B; Pieber TR
Diabetes Obes Metab; 2014 Jan; 16(1):57-62. PubMed ID: 23841569
[TBL] [Abstract][Full Text] [Related]
9. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
[TBL] [Abstract][Full Text] [Related]
10. The use of insulin detemir during pregnancy: a safety evaluation.
Koren R; Toledano Y; Hod M
Expert Opin Drug Saf; 2015 Apr; 14(4):593-9. PubMed ID: 25731934
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU
Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
[TBL] [Abstract][Full Text] [Related]
12. Insulin detemir: from concept to clinical experience.
Home P; Kurtzhals P
Expert Opin Pharmacother; 2006 Feb; 7(3):325-43. PubMed ID: 16448327
[TBL] [Abstract][Full Text] [Related]
13. Insulin detemir versus glyburide in women with gestational diabetes mellitus.
Koren R; Ashwal E; Hod M; Toledano Y
Gynecol Endocrinol; 2016 Nov; 32(11):916-919. PubMed ID: 27597308
[TBL] [Abstract][Full Text] [Related]
14. Investigations of Albumin-Insulin Detemir Complexes Using Molecular Dynamics Simulations and Free Energy Calculations.
Ryberg LA; Sønderby P; Bukrinski JT; Harris P; Peters GHJ
Mol Pharm; 2020 Jan; 17(1):132-144. PubMed ID: 31790268
[TBL] [Abstract][Full Text] [Related]
15. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
Hermansen K; Dornhorst A; Sreenan S
Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
[TBL] [Abstract][Full Text] [Related]
16. A subcutaneous insulin pharmacokinetic model for insulin Detemir.
van Noorden B; Knopp JL; Chase JG
Comput Methods Programs Biomed; 2019 Sep; 178():1-9. PubMed ID: 31416537
[TBL] [Abstract][Full Text] [Related]
17. Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin detemir using continuous glucose monitoring: a randomized, cross-over, pilot study.
Takahashi H; Nishimura R; Onda Y; Ando K; Tsujino D; Utsunomiya K
Expert Opin Pharmacother; 2017 Mar; 18(4):335-342. PubMed ID: 28234565
[TBL] [Abstract][Full Text] [Related]
18. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies.
Heise T; Pieber TR
Diabetes Obes Metab; 2007 Sep; 9(5):648-59. PubMed ID: 17645556
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes.
Herrera KM; Rosenn BM; Foroutan J; Bimson BE; Al Ibraheemi Z; Moshier EL; Brustman LE
Am J Obstet Gynecol; 2015 Sep; 213(3):426.e1-7. PubMed ID: 26070699
[TBL] [Abstract][Full Text] [Related]
20. Identification of recombinant human insulin and biosynthetic insulin analogues by multiplexed targeted unlabeled mass spectrometry of proteotypic tryptic peptides.
Qasem RJ; Aldawsari AS; Almutairi FE; Alsadoon AS
J Pharm Biomed Anal; 2019 Aug; 172():357-363. PubMed ID: 31096094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
